In the last trading session, 1.04 million Cardiff Oncology Inc (NASDAQ:CRDF) shares changed hands as the company’s beta touched 1.52. With the company’s per share price at $3.15 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $209.56M. CRDF’s last price was a discount, traded about -79.05% off its 52-week high of $5.64. The share price had its 52-week low at $2.01, which suggests the last value was 36.19% up since then. When we look at Cardiff Oncology Inc’s average trading volume, we note the 10-day average is 1.53 million shares, with the 3-month average coming to 1.21 million.
Analysts gave the Cardiff Oncology Inc (CRDF) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRDF as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
The company’s shares are showing year-to-date upside of 34.62%, with the 5-day performance at -0.32% in the red. However, in the 30-day time frame, Cardiff Oncology Inc (NASDAQ:CRDF) is -5.69% down. Looking at the short shares, we see there were 17.29 million shares sold at short interest cover period of 17.21 days.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.36%. The 2025 estimates are for Cardiff Oncology Inc earnings to increase by 15.19%, but the outlook for the next 5-year period is at -7.49% per year.
CRDF Dividends
Cardiff Oncology Inc is expected to release its next quarterly earnings report on 2025-May-08.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.64% of Cardiff Oncology Inc shares while 45.29% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 47.99%. There are 45.29% institutions holding the Cardiff Oncology Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.8637% of the shares, roughly 2.63 million CRDF shares worth $5.84 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.766% or 2.14 million shares worth $4.74 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.52 shares estimated at $4.8 million under it, the former controlled 2.29% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.18% of the shares, roughly 1.45 shares worth around $4.57 million.
